BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of rimegepant in the acute treatment of migraine.... Nov 23
Under the terms of the transaction, Catalent acquires Bone Therapeutics’ cell therapy manufacturing subsidiary, SCTS, for gross proceeds of €12 million... Nov 18
The drug delivery innovation major launches Softgel for Pharmaceutical and Nutraceutical Applications... Oct 24
Manufacturing agreement for Autologous T-Cell Receptor-Based Cell Therapy... Sep 24
Catalent and Astrazeneca partners for the Covid vaccine manufacturing... Aug 26
Phase 1 trials establishes the safety level of Moderna's vaccine candidate... Jul 16
Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate... Jun 26
Catalent partners with ViralClear Pharmaceuticals on a potential treatment for COVID-19 ... Jun 25
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
